A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy (NCT05707377)

🧪 Interventions in This Study

• Zanubrutinib (DRUG)
• Tacrolimus (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (47 Sites)

Showing the first 25 of 47 sites.

• Amicis Research Center — Granada Hills, California
• Stanford University — Palo Alto, California
• Intermed Consultants — Minneapolis, Minnesota
• Kidney Specialist of Southern Nevada (Ksosn) — Las Vegas, Nevada
• University of Cincinnati College of Medicine — Cincinnati, Ohio
• Carolina Nephrology — Spartanburg, South Carolina
• Instituto Pro Renal Brasil — Curitiba,
• Ott Healthcare, Inc (Corporate Medical Centre) — Scarborough Village, Ontario
• Beijing An Zhen Hospital, Capital Medical University — Beijing, Beijing Municipality
• Peking University First Hospital — Beijing, Beijing Municipality
• Fujian Medical University Union Hospital — Fuzhou, Fujian
• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian
• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian
• Guangdong Provincial Peoples Hospital — Guangzhou, Guangdong
• The First Affiliated Hospital, Sun Yat Sen University — Guangzhou, Guangdong
• Peking University Shenzhen Hospital — Shenzhen, Guangdong
• The First Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi
• Guizhou Provincial Peoples Hospital — Guiyang, Guizhou
• The First Hospital of Hebei Medical University — Shijiazhuang, Hebei
• The Second Affiliated Hospital of Harbin Medical University — Harbin, Heilongjiang
• Nanyang Central Hospital — Nanyang, Henan
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
• Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei
• Renmin Hospital of Wuhan University — Wuhan, Hubei
• The First Affiliated Hospital of Baotou Medical College — Baotou, Inner Mongolia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Primary Membranous Nephropathy

• A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — San Francisco, California
• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) — Montgomery, Alabama
• Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) — Loma Linda, California
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Huntsville, Alabama
• A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy — Denver, Colorado

Explore by condition: All Primary Membranous Nephropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.